Benefits
Upper respiratory symptom duration
A randomized double-blind placebo-controlled trial in healthy adults gave >=1x10^9 CFU L. casei 431® daily with influenza vaccination and shortened the average duration of upper respiratory symptoms from 7.3 to 6.4 days over the final 3 weeks. The trial's primary endpoint was the antibody response to the vaccine, and it was not met. Symptom duration was a secondary outcome, and neither the number of episodes nor how severe they were differed from placebo. The trial was funded and staffed by the company that sells the strain.
Pollen allergy (KW3110, Kirin)
L. paracasei KW3110, given as 4x10^10 CFU/day yogurt to pollen allergy patients, was associated with repression of Th2 cell generation and eosinophil activation. This was a small double-blind study, 14 people per group, run by the strain's manufacturer and compared against another probiotic yogurt rather than a placebo. It tracked blood immune markers rather than how people actually felt, so on its own it does not show symptom relief.
Pediatric allergic rhinitis (GM-080)
In children with perennial allergic rhinitis, 2x10^9 CFU/day GM-080 for 3 months improved sneezing and Investigator Global Assessment Scale scores compared with placebo. The composite total nasal symptom score, which is the standard overall measure in allergic rhinitis, did not improve significantly, so one symptom moved while the overall symptom score did not. Two of the authors work for GenMont Biotech, which makes GM-080 and paid for the study.
Allergic rhinitis (NCC2461, Nestlé)
NCC2461 (Nestlé) — early nasal provocation studies in around 30 volunteers each were mixed, with one showing less nasal congestion than placebo and another showing less nasal itch but no change in congestion. When the strain was then tested in the field, a 131-person 8-week trial run during grass pollen season found no difference from placebo in symptom scores, quality of life or specific IgE. That negative field result is the most relevant evidence for this strain. Distinct strain-specific evidence base — should not be assumed equivalent to other L. paracasei strains.
Chronic allergy (IJH-SONE68 plant-derived)
In a 60-person 12-week randomized trial, IJH-SONE68 improved subjects' own scores for allergic status, with head dullness, watery eyes and frequency of nose-blowing and sneezing the individual items that moved. A visual analogue scale for difficulty in daily life did not differ from placebo, and the blood markers that improved were liver enzymes rather than allergy markers. The strain was isolated from a fig leaf and cultured in pineapple juice broth, so it suits people avoiding dairy, and the study was funded by the company that supplies it.
Probiotics as a class in allergic rhinitis (30-trial meta-analysis)
A meta-analysis of 30 randomized trials of probiotics in allergic rhinitis (2,708 patients) found better Rhinitis Quality of Life scores and a better nasal symptom subscore, while the global total symptom score, blood eosinophil count, total IgE and antigen-specific IgE were all unchanged. It pooled a wide mix of probiotic species rather than L. paracasei on its own, so it is background for the category rather than evidence for this species. Honest framing: probiotic AR benefits are symptomatic, not immunological — clinical relevance present but mechanistic understanding incomplete.
Mechanism of action
Th1 induction and Th2 repression
Distinguishing immunomodulation profile — shifts the balance toward Th1 (which is suppressive of allergic Th2 responses). Most of this comes from mouse cells and from blood markers in small studies, and the shift has not been shown to track with how people actually feel.
TLR2 and dendritic cell activation
Lactic acid bacteria including L. paracasei can engage TLR2 on dendritic cells, which influences downstream T cell polarization. This is laboratory work, and none of the human trials described on this page measured it.
Exopolysaccharide (EPS) bioactivity (IJH-SONE68)
IJH-SONE68 produces an unusual exopolysaccharide whose anti-allergic activity has been shown in contact dermatitis model mice. It is a strain-specific feature that may underlie its effects, but the link to the human results has not been tested.
Strain-specific bioactive profiles
L. casei 431® vs KW3110 vs NCC2461 vs GM-080 vs IJH-SONE68 each have distinct bioactive profiles. Strain-level chemistry differs; clinical evidence cannot be transferred between strains.
Eosinophil activation suppression
KW3110 — showed no rise in eosinophil activation markers across a pollen season, in a study with 14 people per group compared against another probiotic rather than a placebo. Larger pooled analyses of probiotics in allergic rhinitis found no change in blood eosinophil count.
Mucosal vs systemic immunity (vaccine response evidence)
Respiratory symptom benefit occurs without vaccine antibody response improvement — which has led researchers to suggest the strain acts at the mucosal level rather than by boosting systemic antibodies. Mucosal immunity was not measured in that trial, so this remains a hypothesis rather than a demonstrated mechanism.
Clinical trials
Randomized, double-blind, placebo-controlled, parallel-group trial in 1,104 healthy adults; 42 days of an acidified milk drink providing at least 1x10^9 CFU L. casei 431 or placebo, with seasonal influenza vaccination on day 21.
healthy adults
Jespersen L et al. 2015 (Am J Clin Nutr 101:1188-1196). Randomized double-blind placebo-controlled trial in 1,104 healthy adults aged 18-60 at 2 centers (Germany and Denmark). ≥1×10⁹ CFU L. casei 431® for 42 days with day-21 influenza vaccination. The primary endpoint was the seroprotection rate for anti-influenza antibody titers 21 days after vaccination, and it was not met: there was no effect on any component of the immune response to the vaccine. Shorter upper respiratory symptom duration was a secondary outcome (6.4 versus 7.3 days) seen only in the final 3 weeks of the study, and there was no significant difference in the incidence or severity of those symptoms. The trial was run with Chr. Hansen, which sells the strain.
122 pediatric perennial allergic rhinitis patients on 2×10⁹ CFU/day GM-080 for 3 months.
122 children with perennial allergic rhinitis, given 2 x 10^9 CFU/day of the GM-080 strain for 3 months.
122 pediatric perennial allergic rhinitis patients on 2×10⁹ CFU/day GM-080 for 3 months. At the 2x10^9 CFU/day dose, sneezing and Investigator Global Assessment Scale scores improved significantly versus placebo, but the total nasal symptom score, the standard composite outcome in allergic rhinitis, did not, and the fall in IgE was also not significant. The children were randomized across several GM-080 doses plus placebo, so only 31 of the 122 received this dose. The paper also reports a separate mouse airway study, and the IL-12 results come from mouse cells; in the children, serum interferon-gamma rose only as a nonsignificant trend. Two authors are employees of GenMont Biotech, which funded the work and supplied the probiotic.
60 chronic allergy subjects on IJH-SONE68 for 12 weeks.
60 adults with chronic allergy symptoms, given the IJH-SONE68 strain for 12 weeks.
60 chronic allergy subjects took IJH-SONE68 or placebo for 12 weeks at about 5x10^5 cells per day, a very low cell count for a probiotic. Self-assessed allergy scores improved significantly, driven by head dullness, watery eyes and frequency of nose-blowing and sneezing. A visual analogue scale for difficulty in daily life did not differ from placebo, and the serum markers that improved were liver enzymes rather than allergy or inflammation markers. The strain was isolated from a fig leaf and grown in pineapple juice broth, so it suits people avoiding dairy. Funded by Sone Farm, which supplies the strain.